Neurological & Neuromuscular
Also called partial epilepsy, localization-related epilepsy, focal onset seizures, temporal lobe epilepsy
Focal epilepsy occurs when abnormal electrical activity repeatedly starts in a specific region of the brain. Unlike generalized epilepsy, which involves both brain hemispheres from the start, focal seizures begin in one area and may or may not spread.
Can develop at any age but most commonly begins in childhood or after age 60. Affects males and females roughly equally. Risk factors include head injury, stroke, brain tumors, brain infections, and genetic predisposition. Temporal lobe epilepsy is the most common subtype in adults.
Drug-resistant focal epilepsy is a major area of clinical trial activity. Biohaven's opakalim (BHV-7000), a Kv7 ion channel activator, is in Phase 3 trials for focal epilepsy with topline results expected in 2026. Other active areas include cenobamate optimization studies, antisense oligonucleotides for genetic forms, novel neuromodulation devices, and gene therapy approaches. The Epilepsy Foundation maintains a trial matching service, and comprehensive epilepsy centers often have dedicated research programs enrolling patients with treatment-resistant seizures.
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...